Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma

Cancer Cell International

Volumn 6, Issue , 2006, Pages

  Savas, Burhan ^a,b   Kerr, Pauline E ^b   Pross, Hugh F ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CD56 ANTIGEN; CELL ADHESION MOLECULE; GLYCOPROTEIN P; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE FUNCTION; LYMPHOKINE ACTIVATED KILLER CELL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION;

EID: 33845455795     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-6-24     Document Type: Article

References (42)

1. Wood WC, Muss HB, Solin LJ, Olopade OI: Malignant tumors of the breast. In Cancer Principle and Practice of Oncology Volume Chapter 33.2. 7th edition. Edited by: DeVita VT, Hellman S, Rosenberg SA. Lippincott Williams and Wilkins, Philadelphia; 2005:1415-1477.
2. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton JC, Goldstein LJ: Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 1998, 4:1533-1542.
3. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M: P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989, 60:815-818.
4. Yang X, Uziely B. Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, Press MF: Mdr1 gene expression in primary and advanced breast cancer. Lab Invest 1999, 79:271-280.
5. Harris J, Morrow M, Norton L: Malignant tumors of the breast. In Cancer Principles and Practice of Oncology Edited by: DeVita VT, Hellman S, Rosenberg SA. Lippincott-Raven: Philadelphia, NewYork: 1997:1557-1616.
6. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. New England Journal of Medicine 2005, 353(16):1734-1736.
7. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer. prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16:413-428.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith A, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G. Huang C-S, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz LI, Iwata H, Thomssen C, Lobrisch C, Suter TM, Rüschoff J, Sütö T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci S, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 2005, 353(16):1659-1672.
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Soonmyung P, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 2005, 353(16):1673-1684.
10. Savas B, Karaveli S, Uslu G, Basaran L: Significance of p53 and Cerb-B2 for predicting response to CMF treatment in breast. carcinoma. ASCO Proceedings 1999, 18:. Abst 378 (Abstract)
11. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ: Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15:2894-2904.
12. Slamon D, Clark G, Wong S: Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:117-128.
13. Brinkmann OA, Bruns F, Prott F-J, Hertle L: Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma. Anticancer Res 1999, 19:1583-1588.
14. Savas B, Arslan G, Gelen T, Karpuzoglu G, Ozkaynak C: Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res 1999, 19:4413-4420.
15. Savas B, Kerr PE, Ustun H, Cole SP, Pross HF: Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma. Anticancer Res 1998, 18:4355-4361.
16. Savas B, Cole SP, Tsuruo T, Pross HF: P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma. J Clin Immunol 1996, 16:348-357.
17. Scheper RJ, Bulte JW, Brakkee JG, Quak JJ, van der Schoot E, Balm AJ, Meijer CJ, Broxterman HJ, Kuiper CM, Lankelma J: Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer 1988, 42:389-394.
18. Allavena P, Grandi M, D'Incalci M, Geri O, Giuliani FC, Mantovani A: Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. Int J Cancer 1987, 40:104-107.
19. Gambacorti-Passerini C, Rivoltini L, Supino P, Rodolfo M, Radrizzani M, Fossati G, Parmiani G: Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 1988, 48:2372-2376.
20. Rivoltini L, Cattoretti G, Arienti F, Mastroianni A, Melani C, Colombo MP, Parmiani G: The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int J Cancer 1991, 47:746-754.
21. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J: Human natural killer cell adhesion molecules. differential expression after activation and participation in cytolysis. J Immunol 1990, 145:3194-3201.
22. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, Coon JS: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51:2720-2726.
23. Akiyama S, Fojo A, Hanover J: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genet 1985, 11:117-126.
24. Weinstein RS, Kuszak JR, Klusens LF: P-glycoproteins in pathology: the multidrug resistance gene family in humans. Human Pathology 1990, 21:34-48.
25. Grogan T, Guptill V, Scheper R: Altered cell adhesion molecule (CAM) expression in P-gp rich myeloma cells. J Cell Biol 1990, 111:156A-156A.
26. Mazzoni A, Trave F, Fabbri M, Leto G, Ghidoni R: Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment-induced multidrug resistant human ovarian cancer cells. AntiCancer Res 1991, 11:2181-2185.
27. Posada J, Vichi P, Tritton T: Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res 1989, 49:6634-6639.
28. Liu CC, Perussia. B, Cohn ZA, Young JD: Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells. J Exp Med 1986, 164:2061-2076.
29. Montaudon D, Vrignaud P, Londos-Gagliardi D, Robert J: Fluorescence anisotropy of cell membranes of doxorubicin-sensitive and -resistant rodent tumoral cells. Cancer Res 1986, 46:5602-5605.
30. Murphree SA, Tritton TR, Smith PL, Sartorelli AC: Adriamycin-induced changes in the surface membrane of sarcoma 180 ascites cells. Biochim Biophys Acta 1981, 649:317-324.
31. Zarcone D, Tilden AB, Lane VG, Grossi CE: Radiation sensitivity of resting and activated nonspecific cytotoxic cells of T lineage and NK lineage. Blood 1989, 73:1615-1621.
32. Bagli DJ, D'Emilia JC, Summerhayes IC, Steele GD, Barlozzari T: Cha-ras-i oncogene-induced differentiation and natural killer cell resistance in a human colorectal carcinoma cell line. Cancer Res 1990, 50:2518-2523.
33. Hamada H, Tsuruo T: Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumour cells as revealed by monoclonal antibodies. Proc Natl Acad Sci (USA) 1986, 83:7785-7789.
34. Georges E, Tsuruo T, Ling V: Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. J Biol Chem 1993, 268:1792-1798.
35. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982, 155:1823-1841.
36. Garcia M, Derocq D, Freiss G, Rochefort H: Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci (USA) 1992, 89:11538-11542.
37. Medina MA, Garcia de Veas R, Morata P, Lozano J, Sanchez-Jimenez F: Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines [published erratum appears in Breast Cancer Res. Treat 1996; 37(1):97]. Breast Cancer Res Treat 1995, 35:187-194.
38. Chen C, Okayama H: High efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987, 7:2745-2752.
39. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975, 45:321-324.
40. Russell WC, Newman C, Williamson DH: A simple cytochemical technique far demonstration of DNA in cells infected with mycoplasma and viruses. Nature 1975, 253:461-462.
41. Pross HF, Baines MG, Rubin P, Shragge P, Patterson M: Spontaneous human lymphocyte-mediated cytotoxicity against tumour target cells. IX. Quantitation of natural killer cell activity. J Clin Immunol 1981, 1:51-63.
42. Pross HF, Gallinger LA, Rubin P, Baines MG: The use of modified Cunningham chambers for the enumeration of H-rosettes, E-rosettes and lymphocyte-tumor cell conjugates. Int Arch Allergy Appl Immunol 1981, 66:365-371.